Astrazeneca Pharma India advanced 1.21% to Rs 7557.05 after the company's standalone net profit surged to Rs 54.68 crore in Q3 FY25 as compared with Rs 15.80 crore in Q3 FY24.

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

In this video, we analyze the latest Q3 earnings and key developments from top stocks to watch. TVS Motor has signed an MoU with the Karnataka Government to invest ₹2,000 crore over the next five ...

The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

We recently published a list of 10 Safest Dividend Stocks in the UK. In this article, we are going to take a look at where ...

India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...

The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...

Shares of AstraZeneca Pharma India Ltd closed at ₹7,450 on the BSE, down 1.29% ahead of the earnings announcement.

Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintatolimod) ...

National Institutes of Health (NIH) scientists and their colleagues report that a single dose of a broadly neutralizing antibody (bnAb) administered prior to virus exposure protects macaques from ...